In January-February 2017, Russian pharmaceutical manufacturers shipped from their warehouses the medicinal products in the amount of 45.6 billion rubles (ex warehouse prices, including VAT). This is a 19.5% Year Over Year growth when carrying out settlements in rubles. The physical volume of products manufactured within these two months reached 750 million packs, that is not so impressive with a total growth of about 12%.
For manufacturing enterprises, January has traditionally been a month of rather moderate activity. But, even in that period, the companies shipped from their warehouses the medicinal products in the amount of 21.6 billion rubles, which is 42% more than a year earlier. However, despite clear seasonal trends and restoration of normal production schedule, the results reached in February demonstrated the long-term growth of only 5% in ruble terms. But, in physical volumes, the production grew at a significantly higher rate in February than in January.
In January-February 2017, the share of ruble-denominated settlements for deliveries of medicinal products (finished forms and in-bulk products) increased to 95.4% (+1.4%), while the payments in dollars and euros decreased accordingly and now account for only 4.1% of all payments. In addition, there were marked changes in the geography of suppliers: in the first months of 2017, the imports came from 48 countries while, a year earlier, this figure was 50. However, the leaders did not change, with deliveries from Germany (17% of the total imports in monetary terms) and Netherlands (11.1%) remaining at the top of the list in this period.